VERAXA’s tumor-specific, dual-targeting BiTAC-ADC technology abolishes off-tumor toxicity of ADCs

The primary limitation of ADCs is their systemic toxicity. This is caused by the fact, that only 1% of the injected dose actually reaches the tumor site, whereas 99% of the cytotoxic payload is catabolized off-tumor, causing toxicity in healthy tissues.

VERAXAis applying dual-targeting ADC concepts to broaden the therapeutic window of targeted chemotherapies. Here, we highlight the next generation in tumor-selective dual-targeting concepts for ADCs: VERAXA’s BiTAC-ADC platform, which enables selective killing of tumor cells while sparing healthy tissue.

Here we showcase in vitro and in vivo proof-of-concept data for selected antigen pairs to underline feasibility and to shed light on the underlying concept and mechanism of prodrug activation.

‍